Neuronetics Announces Preliminary Fourth Quarter and Full Year Revenue
Malvern, PA, January 7, 2019 –(PRWirePro.com)– Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced certain unaudited preliminary fourth quarter and full year 2018 revenue. Preliminary fourth quarter 2018 revenue of approximately $15.6 million, an increase of approximately 29% over the fourth quarter of 2017. Preliminary fourth quarter 2018 U.S. treatment session revenue of approximately $9.9 million, an increase of approximately 23% over the fourth quarter of 2017.